These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9880299)

  • 1. Patients with prostate cancer should be enrolled in a national, controlled trial.
    Willis RG
    BMJ; 1999 Jan; 318(7176):126. PubMed ID: 9880299
    [No Abstract]   [Full Text] [Related]  

  • 2. The prostate cancer treatment bazaar: comment on "Physician visits prior to treatment for clinically localized prostate cancer".
    Barry MJ
    Arch Intern Med; 2010 Mar; 170(5):450-2. PubMed ID: 20212181
    [No Abstract]   [Full Text] [Related]  

  • 3. Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists.
    Kim SP; Gross CP; Nguyen PL; Smaldone MC; Shah ND; Karnes RJ; Thompson RH; Han LC; Yu JB; Trinh QD; Ziegenfuss JY; Sun M; Tilburt JC
    Med Care; 2014 Jul; 52(7):579-85. PubMed ID: 24926704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urologists' personal feelings on PSA screening and prostate cancer treatment.
    Wenzler DL; Rosenberg BH
    J Eval Clin Pract; 2014 Aug; 20(4):408-10. PubMed ID: 24798149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prostate cancer in Scandinavia. Variations in practice and attitude to radical treatment].
    Heggestad T; Jonsson PM; Danneskiold-Samsøe B; Leisti S
    Nord Med; 1993; 108(4):104-6. PubMed ID: 8479895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is prostate cancer screening responsible for the negative results of prostate cancer treatment trials?
    Prasad V
    Med Hypotheses; 2016 Aug; 93():71-3. PubMed ID: 27372859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Change in prostate cancer presentation coinciding with USPSTF screening recommendations at a community-based urology practice.
    Gaylis FD; Choi JE; Hamilton Z; Dato P; Cohen E; Calabrese R; Prime H; Rosenbaum A; Kader AK
    Urol Oncol; 2017 Nov; 35(11):663.e1-663.e7. PubMed ID: 28736250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dilemmas in treating early prostate cancer: the evidence and a questionnaire survey of consultant urologists in the United Kingdom.
    Donovan JL; Frankel SJ; Faulkner A; Selley S; Gillatt D; Hamdy FC
    BMJ; 1999 Jan; 318(7179):299-300. PubMed ID: 9924055
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate Cancer Screening - A Perspective on the Current State of the Evidence.
    Pinsky PF; Prorok PC; Kramer BS
    N Engl J Med; 2017 Mar; 376(13):1285-1289. PubMed ID: 28355509
    [No Abstract]   [Full Text] [Related]  

  • 10. Localised prostate cancer: which way forward?
    Stuart-Harris R; Berry MP
    Med J Aust; 1995 Feb; 162(3):116-7. PubMed ID: 7531812
    [No Abstract]   [Full Text] [Related]  

  • 11. [Radical prostatectomy with neoadjuvant hormone therapy for cT3 prostate cancer].
    Fujimoto H
    Nihon Rinsho; 2005 Feb; 63(2):271-8. PubMed ID: 15714978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What urologists say they do for men with prostate cancer.
    Emberton M
    BMJ; 1999 Jan; 318(7179):276. PubMed ID: 9924036
    [No Abstract]   [Full Text] [Related]  

  • 13. Update: NCCN prostate cancer Clinical Practice Guidelines.
    Scardino P
    J Natl Compr Canc Netw; 2005 Nov; 3 Suppl 1():S29-33. PubMed ID: 16280109
    [No Abstract]   [Full Text] [Related]  

  • 14. Controversy in managing patients with prostate cancer. Banish dogma, get more data.
    Mulley AG; Barry MJ
    BMJ; 1998 Jun; 316(7149):1919-20. PubMed ID: 9641924
    [No Abstract]   [Full Text] [Related]  

  • 15. New trial data do not end the PSA screening debate.
    Vastag B
    J Natl Cancer Inst; 2009 Jun; 101(12):844-5. PubMed ID: 19509364
    [No Abstract]   [Full Text] [Related]  

  • 16. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part III: Management strategies and outcomes.
    Barry MJ; Fleming C; Coley CM; Wasson JH; Fahs MC; Oesterling JE
    Urology; 1995 Sep; 46(3):277-89. PubMed ID: 7544931
    [No Abstract]   [Full Text] [Related]  

  • 17. The need to measure quality of life in a prostate cancer screening trial.
    Iverson D
    Can J Oncol; 1994 Nov; 4 Suppl 1():76-7. PubMed ID: 8853496
    [No Abstract]   [Full Text] [Related]  

  • 18. Differences in practice patterns between urologists and radiation oncologists in the management of localized prostate cancer: a cross-sectional survey.
    Ariane MM; Ploussard G; Rebillard X; Malavaud B; Rischmann P; Hennequin C; Mongiat-Artus P
    World J Urol; 2015 Nov; 33(11):1741-7. PubMed ID: 25822706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AUA's response to the OTA study on prostate cancer screening for elderly men.
    Oncology (Williston Park); 1995 Nov; 9(11):1123. PubMed ID: 8703675
    [No Abstract]   [Full Text] [Related]  

  • 20. Differences between urologists in the United States and Canada in the approach to prostate cancer.
    Fleshner N; Rakovitch E; Klotz L
    J Urol; 2000 May; 163(5):1461-6. PubMed ID: 10751858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.